Aeluma (ALMU) 10-Q 15 May 23 2023 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2023	May 10, 2023
Document Information Line Items
Entity Registrant Name	Aeluma, Inc.
Trading Symbol	N/A
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		12,817,500
Amendment Flag	false
Entity Central Index Key	0001828805
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56218
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2807351
Entity Address, Address Line One	27 Castilian Drive
Entity Address, City or Town	Goleta
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
City Area Code	(805)
Local Phone Number	351-2707
Title of 12(g) Security	None
Security Exchange Name	NONE
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Jun. 30, 2022
Current assets:
Cash	$ 4,857,255	$ 3,740,722
Deferred compensation, current portion	268,196	662,464
Prepaids & other current assets	199,360	27,662
Total current assets	5,324,811	4,430,848
Property and equipment:
Equipment	797,995	619,613
Leasehold improvements	541,559	4,666,462
Accumulated depreciation	(242,475)	(96,987)
Total fixed assets	1,097,079	986,988
Intangible assets, net	10,583	12,833
Right of use asset - facility	382,463	476,370
Deferred compensation, long term portion		11,034
Other assets	13,014	13,014
Total assets	6,827,950	5,931,087
Current liabilities:
Accounts payable	457,648	114,100
Accrued expenses & other current liabilities	167,282	101,351
Lease liability, current portion	160,882	156,988
Total current liabilities	785,812	372,439
Lease liability, long term portion	337,888	458,705
Commitments and contingencies
Total liabilities	1,123,700	831,144
Stockholders’ equity:
Preferred stock, par value $0.0001, 10,000,000 authorized, none issued and outstanding.
Common stock, par value $0.0001, and 50,000,000 shares authorized, 12,247,334 and 10,650,002 shares issued and outstanding at March 31, 2023 and June 30, 2022, respectively.	1,225	1,066
Additional paid-in capital	13,456,900	8,781,361
Accumulated deficit	(7,753,875)	(3,682,484)
Total stockholders’ equity	5,704,250	5,099,943
Total liabilities and stockholders’ equity	$ 6,827,950	$ 5,931,087

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2023	Jun. 30, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	12,247,334	10,650,002
Common stock, shares outstanding	12,247,334	10,650,002

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue
Operating expenses:
Research & development	428,748	343,133	1,650,281	619,174
General & administrative	841,614	446,977	2,000,011	1,192,810
Facility	103,505	99,086	352,476	314,901
Insurance	94,629	81,219	287,309	243,120
Total expenses	1,568,496	970,415	4,290,077	2,370,005
Loss from operations	(1,568,496)	(970,415)	(4,290,077)	(2,370,005)
Other income:
Sub-lease rental income & other income	107,426	55,689	217,942	227,589
Interest income	269	349	744	1,694
Total other income	107,695	56,038	218,686	229,283
Loss before income tax expense	(1,460,801)	(914,377)	(4,071,391)	(2,140,722)
Income tax expense
Net loss	$ (1,460,801)	$ (914,377)	$ (4,071,391)	$ (2,140,722)
Basic and diluted loss per share (in Dollars per share)	$ (0.13)	$ (0.09)	$ (0.37)	$ (0.2)
Weighted average common shares outstanding - basic and diluted (in Shares)	11,518,154	10,650,002	10,983,045	10,650,002

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Basic and diluted loss per share (in Dollars per share)	$ (0.13)	$ (0.09)	$ (0.37)	$ (0.20)
Weighted average common shares outstanding - basic and diluted	11,518,154	10,650,002	10,983,045	10,650,002

Consolidated Statement of Stock

Consolidated Statement of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in capital	Accumulated Deficit	Total
Balance at Jun. 30, 2021	$ 1,054	$ 8,415,432	$ (230,922)	$ 8,185,564
Balance (in Shares) at Jun. 30, 2021	10,535,002
Issuance of common stock, net of offering costs	$ 12	206,918		206,930
Issuance of common stock, net of offering costs (in Shares)	115,000
Other offering costs		(45,000)		(45,000)
Stock-based compensation		70,782		70,782
Net income (loss)			(2,140,722)	(2,140,722)
Balance at Mar. 31, 2022	$ 1,066	8,648,132	(2,371,644)	6,277,554
Balance (in Shares) at Mar. 31, 2022	10,650,002
Balance at Dec. 31, 2021	$ 1,066	8,607,018	(1,457,267)	7,150,817
Balance (in Shares) at Dec. 31, 2021	10,650,002
Stock-based compensation		41,114		41,114
Net income (loss)			(914,377)	(914,377)
Balance at Mar. 31, 2022	$ 1,066	8,648,132	(2,371,644)	6,277,554
Balance (in Shares) at Mar. 31, 2022	10,650,002
Balance at Jun. 30, 2022	$ 1,066	8,781,361	(3,682,484)	5,099,943
Balance (in Shares) at Jun. 30, 2022	10,650,002
Issuance of common stock, net of offering costs	$ 144	4,071,001		4,071,145
Issuance of common stock, net of offering costs (in Shares)	1,447,332
Issuance of shares for services	$ 15	299,985		300,000
Issuance of shares for services (in Shares)	150,000
Stock-based compensation		304,553		304,553
Net income (loss)			(4,071,391)	(4,071,391)
Balance at Mar. 31, 2023	$ 1,225	13,456,900	(7,753,875)	5,704,250
Balance (in Shares) at Mar. 31, 2023	12,247,334
Balance at Dec. 31, 2022	$ 1,132	10,685,361	(6,293,074)	4,393,419
Balance (in Shares) at Dec. 31, 2022	11,317,002
Issuance of common stock, net of offering costs	$ 93	2,644,437		2,644,530
Issuance of common stock, net of offering costs (in Shares)	930,332
Stock-based compensation		127,102		127,102
Net income (loss)			(1,460,801)	(1,460,801)
Balance at Mar. 31, 2023	$ 1,225	$ 13,456,900	$ (7,753,875)	$ 5,704,250
Balance (in Shares) at Mar. 31, 2023	12,247,334

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders’ Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Net of offering costs	$ 146,470	$ 270,855	$ 23,070

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (4,071,391)	$ (2,140,722)
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of shares for services	300,000
Amortization of deferred compensation	405,302	497,302
Partial refund of facility lease deposit		52,055
Stock-based compensation expense	304,553	70,782
Depreciation and amortization expense	147,738	52,182
Change in prepaids & other current assets	(171,698)	(84,094)
Change in accounts payable	343,548	30,408
Change in accrued expenses & other current liabilities	42,915	105,248
Net cash used in operating activities	(2,699,033)	(1,416,839)
Investing activities:
Purchase of equipment	(178,382)	(285,382)
Payment for leasehold improvements	(77,197)	(431,117)
Net cash used in investing activities	(255,579)	(716,499)
Financing activities:
Proceeds from Private Placement	4,071,145	206,930
Payment of other offering costs		(45,000)
Net cash provided by financing activities	4,071,145	161,930
Net change in cash	1,116,533	(1,971,408)
Cash, beginning of period	3,740,722	6,787,250
Cash, end of period	$ 4,857,255	$ 4,815,842

The Company

The Company	9 Months Ended
	Mar. 31, 2023
The Company [Abstract]
The Company	Note 1 – The Company Aeluma is headquartered in Goleta, California. The Company is engaged in the research and development of infrared (IR) optical sensors to disrupt the market for IR sensors, and using its proprietary technology aims to produce a much higher performance alternative to today’s low-cost sensors at much lower prices than would otherwise be possible. The focus of the Company will be the image sensor market. Initial efforts hope to penetrate the 3D imaging and sensing (mobile and consumer, defense and aerospace, industrial, medical, auto) and LiDAR (robotic vehicles, advanced driver assistance systems vehicles (ADAS), topography, wind, industrial) markets. We were originally incorporated as Parc Investments, Inc. in the State of Delaware on August 21, 2020. Prior to the Merger (as defined below), we were a “shell company” (as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)). On June 22, 2021, our board of directors and all of our pre-Merger stockholders approved a restated certificate of incorporation, which was effective upon its filing with the Secretary of State of the State of Delaware on June 22, 2021 and through which we changed our name to “Aeluma, Inc.” On June 22, 2021, our board of directors also adopted restated bylaws. On June 22, 2021, Biond Photonics, Inc., a privately held California corporation (“Biond Photonics”) merged with and into our wholly-owned subsidiary, Aeluma Operating Co., a corporation formed in the State of Delaware on June 22, 2021 (“Acquisition Sub”). Pursuant to this transaction (the “Merger”), Acquisition Sub was the surviving corporation and remained our wholly-owned subsidiary, and all the outstanding stock of Biond Photonics was converted into shares of our common stock. As a result of the Merger, we acquired the business of Biond Photonics and continued the existing business operations of Biond Photonics as a public reporting company under the name Aeluma, Inc. In conjunction with the merger transaction, the company changed its year end to June 30. Biond Photonics was incorporated in February 2019. Merger Agreement On June 22, 2021, Parc Investments, Inc., Acquisition Sub and Biond Photonics entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, on June 22, 2021 (the “Closing Date”), Biond Photonics merged with and into Acquisition Sub, with Acquisition Sub continuing as the surviving corporation and our wholly-owned subsidiary. As a result of the Merger, we acquired the business of Biond Photonics, a California corporation, doing business as Aeluma. At the time the certificates of merger reflecting the Merger were filed with the Secretaries of State of California and Delaware (the “Effective Time”), each of Biond Photonics’ shares of capital stock issued and outstanding immediately prior to the closing of the Merger was converted into the right to receive (a) 1.299135853 shares of our common stock (the “Common Share Conversion Ratio”), with the maximum number of shares of our common stock issuable to the former holders of Biond Photonics’ capital stock equal to 4,100,000 after adjustments due to rounding for fractional shares. Immediately prior to the Effective Time, an aggregate of 2,500,000 shares of our common stock owned by our stockholders prior to the Merger were forfeited and cancelled (the “Stock Forfeiture”). The issuance of shares of our common stock to Biond Photonics’ former security holders are collectively referred to as the “Share Conversion.” The Merger Agreement contained customary representations and warranties and pre- and post-closing covenants of each party and customary closing conditions. As a condition to the Merger, we entered into an indemnity agreement with our former officer and directors (the “Pre-Merger Indemnity Agreement”), pursuant to which we agreed to indemnify such former officer and directors for actions taken by them in their official capacities relating to the consideration, approval and consummation of the Merger and certain related transactions. The Merger was treated as a recapitalization and reverse acquisition for financial reporting purposes. Biond Photonics is considered the acquirer for accounting purposes, and our historical financial statements before the Merger will be replaced with the historical financial statements of Biond Photonics before the Merger in future filings with the SEC. The Merger is intended to be treated as a tax-free reorganization under Section 368(a) of the Internal Revenue Code of 1986, as amended.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited interim consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The consolidated financial statements as of March 31, 2023 and 2022, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on September 28, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for their integrity and objectivity. Going Concern The Company incurred a net loss of $3,451,699 and $4,071,391 for the year ended June 30, 2022 and the nine months ended March 31, 2023, respectively. In addition, the Company is in the research and development stage and has not generated revenue to date. In order to support its operations, the Company will require additional infusions of cash from the sale of equity instruments or the issuance of debt instruments, or the commencement of profitable revenue generating activities. If adequate funds are not available or are not available on acceptable terms, the Company’s ability to fund its operations, develop or enhance its sensors in the future or respond to competitive pressures would be significantly limited. Such limitations could require the Company to curtail, suspend or discontinue parts of its business plan. These conditions may raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. Basic Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. The number of shares prior to the merger have been restated to consider the conversion into the shares of the legal acquirer. Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Reclassification of Prior Year Presentation For the three and nine months ended March 31, 2022, research & development expenses of $165,956 and $350,195, respectively, have been reclassified for consistency with the current year presentation. Fair Value of Financial Instruments As defined in Financial Accounting Standards Board (“FASB”) ASC Topic No. 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses the market or income approach. Based on this approach, the Company utilizes certain assumptions about the risk inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and the reliability of the information used to determine fair values. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Unadjusted quoted prices in active, accessible market for identical assets or liabilities Level 2 – Other inputs that are directly or indirectly observable in the marketplace Level 3 – Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, accounts payable, and accrued expenses approximate their fair value due to the relatively short maturity of these items. Concentration of Risk The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. Property and Equipment Property, equipment and leasehold improvements are reported at historical cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Equipment is depreciated over five years, and leasehold improvements are amortized over the remaining lease term. Repairs and maintenance to these assets are charged to expense as incurred; major improvements enhancing the function and/or the asset’s useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized. Intangible Assets Intangible assets are associated with the Aeluma.com domain name and are amortized on a straight-line basis over five years. Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents. The Company’s accounts are insured by the FDIC but at times may exceed federally insured limits. Income Taxes The Company is expected to have net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. The Company is currently analyzing the amount of loss carryforwards that will be available to reduce future taxable income. The resulting deferred tax assets will be offset by a valuation allowance due to the uncertainty of its realization. The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before income taxes relates to the recognition of a valuation allowance for deferred income tax assets. The Company has adopted FASB ASC 740-10, “ Income Taxes” The Company will file tax returns in the U.S. federal jurisdiction and the state of California. The Company’s federal and state return form are subject to review by the taxing authorities. The Company is not currently under examination by any taxing authority, nor has it been notified of an impending examination. Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. We account for forfeitures upon occurrence.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Mar. 31, 2023
Stockholders’ Equity [Abstract]
Stockholders’ Equity	Note 3 – Stockholders’ Equity Authorized Shares The Company’s Articles of Incorporation authorize the issuance of two classes of shares of stock. The total number of shares which this corporation is authorized to issue is 50,000,000 shares of $0.0001 par value common stock and 10,000,000 of $0.0001 par value preferred stock. No Common Stock Offering Immediately following the Merger, on June 22, 2021, we sold 3,482,500 shares of our common stock pursuant to an initial closing of a private placement offering at a purchase price of $2.00 per share, with gross proceed of $6,965,000 (before deducting placement agent fees and expenses of $949,736). We held a second closing on June 28, 2021 for an additional 402,500 shares of our common stock, with gross proceed of $805,000 (before deducting placement agent fees and expenses of $109,769) and a third and final close on July 1, 2021 for an additional 115,000, with gross proceed of $230,000 (before deducting placement agent fees and expenses of $23,070). Accordingly, we sold a total of 4,000,000 shares of our common stock with a total gross proceeds of $8,000,000 (before deducting total placement agent fees and expenses of $1,082,577). The private placement offering is referred to herein as the “Offering.” On December 12, 2022, we sold an aggregate of 517,000 shares of common stock in a private placement offering at a price of $3.00 per share, with gross proceeds of $1,551,000 (before deducting placement agent fees and expenses of $124,385). On January 10, 2023, we sold an aggregate of 214,667 shares of common stock, with gross proceeds of $644,000 (before deducting placement agent fees and expenses of $28,640), pursuant to that same private placement. On March 31, 2023, we sold an aggregate of 715,665 shares of common stock, with gross proceeds of $2,147,000 (before deducting placement agent fees and expenses of $117,830), pursuant to the same private placement. Accordingly, as of March 31, 2023, we sold a total of 1,447,332 shares of our common stock with a total gross proceeds of $4,342,000 (before deducting total placement agent fees and expenses of $270,855) in this private placement. The Offering was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC thereunder. The common stock in the Offering was sold to “accredited investors,” as defined in Regulation D, and was conducted on a “reasonable best efforts” basis. Issued and Vested Shares to Officers On October 27, 2020, the Company issued 1,623,920 shares of common stock to Director and CEO Jonathan Klamkin and 1,623,920 shares of common stock to Director, interim CFO and COO, Lee McCarthy for an aggregate sum of $10,000 each. Initially 20% or 324,784 shares vested on October 27, 2020, and the remaining 1,299,136 shares vest in equal amounts, monthly over the subsequent 4 years. The stock purchase agreement contains a repurchase option whereby unvested shares may be repurchased by the Company, at the Company’s option, within 90 days after employee termination. At March 31, 2023, Jonathan Klamkin had 1,109,679 vested shares and 514,241 unvested shares, and Lee McCarthy had 974,350 vested shares and 649,570 unvested shares. Lee McCarthy left the Company in November 2022. Registration Rights Agreement The Company entered into a registration rights agreement that provides for certain liquidated damages upon the occurrence of a “Registration Event,” which is defined as the occurrence of any of the following events: (a) the Company fails to file with the Commission the Registration Statement on or before the Registration Filing Date; (b) the Registration Statement is not declared effective by the Commission on or before the Registration Effectiveness Date; (c) after the SEC Effective Date, the Registration Statement ceases for any reason to remain effective or the Holders of Registrable Securities covered thereby are otherwise not permitted to utilize the prospectus therein to resell the Registrable Securities covered thereby, except for Blackout Periods permitted herein; or (d) following the listing or inclusion for quotation on an Approved Market, the Registrable Securities, if issued and outstanding, are not listed or included for quotation on an Approved Market, or trading of the Common Stock is suspended or halted on the Approved Market, which at the time constitutes the principal markets for the Common Stock, for more than three (3) full, consecutive Trading Days (other than as a result of (A) actions or inactions of parties other than the Company or its affiliates or of the Approved Market not reasonably in the control of the Company, or (B) suspension or halt of substantially all trading in equity securities (including the Common Stock) on the Approved Market). The maximum amount of liquidated damages that may be paid by the Company shall be an amount equal to eight percent (8%) of the shares covered by the registration rights agreement. This filing covered 11,010,002 shares. The Company currently expects to satisfy all of its obligations under the Registration Agreement and does not expect to pay any damages pursuant to this agreement; therefore, no liability has been recorded.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Mar. 31, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 4 – Stock-Based Compensation Restricted Stock Awards During six months ended June 30, 2021, the Company sold 723,008 shares of common stock to certain individuals in exchange for future management advisory services, for discounted prices price ranging from $.0104 to $.0195 per share. The shares are subject to restrictions that allow for repurchase of the shares by the Company due to a termination of the service agreement or other certain provisions. This repurchase right declines on a pro-rata basis over vesting periods (corresponding to the service period) ranging from 2-4 years. Related to these issuances, the Company has recorded deferred stock-based compensation for the value of the shares in excess of the purchase price paid by the advisors. The stock-based compensation is expensed over the service period. For the three months ended March 31, 2023 and 2022, $163,347 and $163,348, respectively, have been amortized in the statements of operations and, for the nine months ended March 31, 2023 and 2022, $497,302 and $497,303, respectively, have been amortized in the statement of operations. At March 31, 2023, $176,196 included in the deferred compensation amount on the balance sheets is expected to be expensed in the next four months. In March 2022, the Company signed an agreement to issue 150,000 shares of common stock valued at $300,000 to a consultant for providing consulting services to the Company for eighteen months. For the three and nine months ended March 31, 2023, $50,000 and $208,000, respectively, has been expensed in general and administrative in the statements of operations. At March 31, 2023, $92,000 included in the deferred compensation amount on the balance sheets is expected to be expensed in the next six months. The 150,000 shares of common stock were issued during nine months ended March 31, 2023. The following is a schedule summarizing restricted stock awards for the periods indicated: March 31, 2023 Three Months Ended Nine Months Ended Number of Weighted Number of Weighted Beginning balance 296,022 $ 1.95 344,426 $ 1.90 Issued - - 150,000 $ 2.00 Vested (124,202 ) $ 1.93 (322,606 ) $ 1.92 Forfeited - - - - Ending balance 171,820 $ 1.95 171,820 $ 1.95 March 31, 2022 Three Months Ended Nine Months Ended Number of Weighted Number of Weighted Beginning balance 517,828 $ 1.90 691,232 $ 1.90 Issued - - - - Vested (86,702 ) $ 1.90 (260,106 ) $ 1.90 Forfeited - - - - Ending balance 431,126 $ 1.90 431,126 $ 1.90 Stock Options In July 2021, the Company issued an option to purchase 10,000 shares of common stock to a director at a price of $2.00 per share, expiring in 10 years, and an option to purchase 10,000 shares of common stock to an advisor at a price of $2.00 per share expiring in 5 years. These options vested over periods ranging from one month to three months. In December 2021, the Company issued options to purchase common stock to two directors in increments of 125,000 each. The options have an exercise price of $2.00, expire in 10 years, vest 12,500 options per quarter in the first year and 9,375 per quarter for the following two years. In February of 2022, the company granted 16,750 in options to one director and 15,500 to another director at a price of $2.00 per share, for committee service. These options are subject to quarterly vesting over four quarters and expire in 10 years. On February 1, 2022, the Company entered into a consulting advisory agreement which grants 2,500 options with every patent filing. On February 4, 2022, the advisor was granted 2,500 options with an exercise price of $2.00 and an expiration date of ten years. In April of 2022, the Company issued 513,000 options to purchase common stock to employees. The options have an exercise price of $2.00 and expire in 10 years with 25% vesting after one year and the remainder scheduled to vest each quarter for three years, subject to the continued status as an employee to the Company through each vesting date. In December of 2022, the Company issued 161,000 options to purchase common stock to employees. The options have an exercise price of $2.00 or $2.10 and expire in 10 years with various vesting schedules from six months to 48 months, subject to the continued status as an employee to the Company through each vesting date. During the three months ended March 31, 2023, the Company issued 109,750 options to purchase common stock to employees and directors. The options have an exercise price of $3.00 and expire in 10 years with various vesting schedules from 12 months to 48 months. Stock options granted to employees are subject to the continued status as an employee to the Company through each vesting date. During the three months ended March 31, 2023, the Company also issued 37,500 conditional options to purchase common stock to non-employee advisors. The options have an exercise price of $3.00 and expire in 10 years, vesting on the date when certain vesting conditions are met. The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions for to estimate the fair value of stock options for directors issued for the nine months ended March 31, 2023 and 2022: Nine Months Ended 2023 2022 Weighted-average fair value $ 2.49 $ 1.48 Expected volatility 100 % 100 % Expected term 5.0 years - 7.0 years 5.0 years Dividend yield 0.00 % 0.00 % Risk-free interest rate 1.26% - 4.24 % 1.15% - 2.41 % For the three months ended March 31, 2023 and 2022, stock-based compensation expenses for options granted were $127,102 and $41,114, respectively. For the nine months ended March 31, 2023 and 2022, stock-based compensation expenses for options granted were $304,553 and $70,783, respectively. Unrecognized stock-based compensation expense was $1,292,801 and average expected recognition period was 2.8 years as of March 31, 2023. The following is a schedule summarizing employee and non-employee stock option activity for the period presented: Number of Options Weighted Aggregate Outstanding at January 1, 2023 858,750 $ 2.01 $ 846,250 Granted 147,250 $ 3.00 Exercised - - Expired/cancelled - - Outstanding at March 31, 2023 1,006,000 $ 2.16 $ 1,449,850 Exercisable at March 31, 2023 307,375 $ 2.02 $ 486,613 (1) Represents the excess of the fair value on the last day of period (which was $3.00 and $3.60 as of December 31, 2022 and March 31, 2023, respectively) over the exercise price, multiplied by the number of options. Number of Options Weighted Average Aggregate Intrinsic Outstanding at January 1, 2022 270,000 $ 2.00 $ - Granted 34,750 $ 2.00 Exercised - - Expired/cancelled - - Outstanding at March 31, 2022 304,750 $ 2.00 $ - Exercisable at March 31, 2022 47,500 $ 2.00 $ - Number of Options Weighted Average Aggregate Intrinsic Outstanding at July 1, 2022 817,750 $ 2.00 $ - Granted 308,250 $ 2.41 Exercised - - Expired/cancelled (120,000 ) $ 2.00 Outstanding at March 31, 2023 1,006,000 $ 2.16 $ 1,449,850 Exercisable at March 31, 2023 307,375 $ 2.02 $ 486,613 (1) Represents the excess of the fair value on the last day of the period (which was $3.60 as of March 31, 2023) over the exercise price, multiplied by the number of options. Number of Options Weighted Average Exercise Price Aggregate Intrinsic Outstanding at July 1, 2021 - $ - $ - Granted 304,750 $ 2.00 Exercised - - Expired/cancelled - - Outstanding at March 31, 2022 304,750 $ 2.00 $ - Exercisable at March 31, 2022 47,500 $ 2.00 $ -

Facility Operating Lease

Facility Operating Lease	9 Months Ended
	Mar. 31, 2023
Facility Operating Lease [Abstract]
Facility Operating Lease	Note 5 – Facility Operating Lease On April 1, 2021, the Company commenced a 5-year operating lease for a facility in Santa Barbara, California with total lease payments of $781,813. The Company determined the lease constitutes a Right of Use (ROU) asset and has recorded the present value of the lease payments as an asset and liability per ASC 842. The value of the asset will be amortized on a straight-line basis over the 60-month period and amortization began at the start of the lease. Additionally, the lease agreement waived the first three months of rent with payments commencing July 2021. At the commencement of the lease, the net present value of the lease payments was 767,553. In addition to these lease payments, the Company is also responsible for its shares of common area operating expenses and electricity. Such expenses are considered variable costs and are not included in the measurement of the lease liability. The lease agreement also provides for the option to extend the lease for two additional sixty-month periods. The lease payments for these additional periods are not included in the lease liability amount presented on the balance sheet. The following table presents maturities of operating lease liabilities on an undiscounted basis as of March 31, 2023: Fiscal 2023 $ 41,017 Fiscal 2024 165,096 Fiscal 2025 169,224 Fiscal 2026 129,283 Total 504,620 Less imputed interest (5,850 ) Total operating lease liability 498,770 Less: current portion 160,882 Lease liability, long term $ 337,888 The lease term and the discount rate for the lease at March 31, 2023 is 3.0 years and 0.75%, respectively. The total lease payments were $24,360 and $39,041 for the three months ended March 31, 2023 and 2022, respectively and $97,078 and $117,124 for the nine months ended March 31, 2023 and 2022, respectively. The variable costs for common area operating expenses and electricity were $54,643 and $55,516 for the three months ended March 31, 2023 and 2022, respectively, and $228,454, and $173,488 for the nine months ended March 31, 2023 and 2022, respectively. Beginning April 1, 2021, the Company began subleasing a portion of their facility. The sub-lease provides for base monthly rent of $13,013 through May 31, 2021 and $8,400 starting June 1, 2021 plus common area operating and utility costs. The sublease was amended again on May 17, 2022 to sublease a smaller portion of the property at a base rental rate of $5,200 per month effective June 1, 2022. Of rental income, including reimbursement of common area operating and utility costs, the Company recognized $23,405 and $55,689 for the three months ended March 31, 2023 and 2022, respectively, and $128,921 and $227,589 for the nine months ended March 31, 2023 and 2022, respectively.

Warrants to Purchase Common Sto

Warrants to Purchase Common Stock	9 Months Ended
	Mar. 31, 2023
Warrants to Purchase Common Stock [Abstract]
Warrants to Purchase Common Stock	Note 6 – Warrants to Purchase Common Stock In connection with the Offering on December 22, 2022, the Company issued warrants of 29,067 to purchase common stock to the Placement Agents. The warrants carry a term of 5 years and an exercise price of $3.00. In connection with the Offering on January 10 and March 31, 2023, the Company issued warrants of 4,933 and 6,720, respectively, to purchase common stock to the Placement Agents. The warrants carry a term of 5 years and an exercise price of $3.00. The following warrants to purchase common stock were outstanding as of March 31, 2023: Number of Shares Exercise Price Expiration Date 360,000 $ 2.00 June 28, 2026 29,067 3.00 December 22, 2027 4,933 3.00 January 10, 2028 6,720 3.00 March 31, 2028 400,720

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 7 – Subsequent Events One May 10, 2023, the Company held the final closing of the Offering, pursuant to which they issued an aggregate of 570,166 shares of its common stock for aggregate gross proceeds of $1,710,500. Pursuant to the final closing, the Company paid a cash placement agent fee in the amount of $136,840 and will issue placement agent warrants to purchase up to 44,933 shares of common stock at an exercise price of $3.00 per share. The Company has evaluated subsequent events and transactions that occurred after March 31, 2023 up through the date the Company issued these unaudited consolidated financial statements on May 15, 2023. All subsequent events requiring recognition as of March 31, 2023 have been incorporated into these unaudited consolidated financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.” Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned thereunto duly authorized.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The consolidated financial statements as of March 31, 2023 and 2022, are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on September 28, 2022. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for their integrity and objectivity.
Going Concern	Going Concern The Company incurred a net loss of $3,451,699 and $4,071,391 for the year ended June 30, 2022 and the nine months ended March 31, 2023, respectively. In addition, the Company is in the research and development stage and has not generated revenue to date. In order to support its operations, the Company will require additional infusions of cash from the sale of equity instruments or the issuance of debt instruments, or the commencement of profitable revenue generating activities. If adequate funds are not available or are not available on acceptable terms, the Company’s ability to fund its operations, develop or enhance its sensors in the future or respond to competitive pressures would be significantly limited. Such limitations could require the Company to curtail, suspend or discontinue parts of its business plan. These conditions may raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.
Basic Net Income (Loss) Per Share	Basic Net Income (Loss) Per Share Basic income (loss) per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. The number of shares prior to the merger have been restated to consider the conversion into the shares of the legal acquirer.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation For the three and nine months ended March 31, 2022, research & development expenses of $165,956 and $350,195, respectively, have been reclassified for consistency with the current year presentation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As defined in Financial Accounting Standards Board (“FASB”) ASC Topic No. 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses the market or income approach. Based on this approach, the Company utilizes certain assumptions about the risk inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and the reliability of the information used to determine fair values. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Unadjusted quoted prices in active, accessible market for identical assets or liabilities Level 2 – Other inputs that are directly or indirectly observable in the marketplace Level 3 – Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, accounts payable, and accrued expenses approximate their fair value due to the relatively short maturity of these items.
Concentration of Risk	Concentration of Risk The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts.
Property and Equipment	Property and Equipment Property, equipment and leasehold improvements are reported at historical cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Equipment is depreciated over five years, and leasehold improvements are amortized over the remaining lease term. Repairs and maintenance to these assets are charged to expense as incurred; major improvements enhancing the function and/or the asset’s useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized.
Intangible Assets	Intangible Assets Intangible assets are associated with the Aeluma.com domain name and are amortized on a straight-line basis over five years.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents. The Company’s accounts are insured by the FDIC but at times may exceed federally insured limits.
Income Taxes	Income Taxes The Company is expected to have net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. The Company is currently analyzing the amount of loss carryforwards that will be available to reduce future taxable income. The resulting deferred tax assets will be offset by a valuation allowance due to the uncertainty of its realization. The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before income taxes relates to the recognition of a valuation allowance for deferred income tax assets. The Company has adopted FASB ASC 740-10, “ Income Taxes” The Company will file tax returns in the U.S. federal jurisdiction and the state of California. The Company’s federal and state return form are subject to review by the taxing authorities. The Company is not currently under examination by any taxing authority, nor has it been notified of an impending examination.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. We account for forfeitures upon occurrence.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2023
Stock-Based Compensation [Abstract]
Schedule of restricted stock awards	March 31, 2023 Three Months Ended Nine Months Ended Number of Weighted Number of Weighted Beginning balance 296,022 $ 1.95 344,426 $ 1.90 Issued - - 150,000 $ 2.00 Vested (124,202 ) $ 1.93 (322,606 ) $ 1.92 Forfeited - - - - Ending balance 171,820 $ 1.95 171,820 $ 1.95 March 31, 2022 Three Months Ended Nine Months Ended Number of Weighted Number of Weighted Beginning balance 517,828 $ 1.90 691,232 $ 1.90 Issued - - - - Vested (86,702 ) $ 1.90 (260,106 ) $ 1.90 Forfeited - - - - Ending balance 431,126 $ 1.90 431,126 $ 1.90
Schedule of estimates the fair value of each option award	Nine Months Ended 2023 2022 Weighted-average fair value $ 2.49 $ 1.48 Expected volatility 100 % 100 % Expected term 5.0 years - 7.0 years 5.0 years Dividend yield 0.00 % 0.00 % Risk-free interest rate 1.26% - 4.24 % 1.15% - 2.41 %
Schedule of summarizing employee and non-employee stock option activity	Number of Options Weighted Aggregate Outstanding at January 1, 2023 858,750 $ 2.01 $ 846,250 Granted 147,250 $ 3.00 Exercised - - Expired/cancelled - - Outstanding at March 31, 2023 1,006,000 $ 2.16 $ 1,449,850 Exercisable at March 31, 2023 307,375 $ 2.02 $ 486,613 Number of Options Weighted Average Aggregate Intrinsic Outstanding at January 1, 2022 270,000 $ 2.00 $ - Granted 34,750 $ 2.00 Exercised - - Expired/cancelled - - Outstanding at March 31, 2022 304,750 $ 2.00 $ - Exercisable at March 31, 2022 47,500 $ 2.00 $ - Number of Options Weighted Average Aggregate Intrinsic Outstanding at July 1, 2022 817,750 $ 2.00 $ - Granted 308,250 $ 2.41 Exercised - - Expired/cancelled (120,000 ) $ 2.00 Outstanding at March 31, 2023 1,006,000 $ 2.16 $ 1,449,850 Exercisable at March 31, 2023 307,375 $ 2.02 $ 486,613 Number of Options Weighted Average Exercise Price Aggregate Intrinsic Outstanding at July 1, 2021 - $ - $ - Granted 304,750 $ 2.00 Exercised - - Expired/cancelled - - Outstanding at March 31, 2022 304,750 $ 2.00 $ - Exercisable at March 31, 2022 47,500 $ 2.00 $ -

Facility Operating Lease (Table

Facility Operating Lease (Tables)	9 Months Ended
	Mar. 31, 2023
Facility Operating Lease [Abstract]
Schedule of maturities of operating lease liabilities	Fiscal 2023 $ 41,017 Fiscal 2024 165,096 Fiscal 2025 169,224 Fiscal 2026 129,283 Total 504,620 Less imputed interest (5,850 ) Total operating lease liability 498,770 Less: current portion 160,882 Lease liability, long term $ 337,888

Warrants to Purchase Common S_2

Warrants to Purchase Common Stock (Tables)	9 Months Ended
	Mar. 31, 2023
Warrants to Purchase Common Stock [Abstract]
Schedule of warrants to purchase common stock	Number of Shares Exercise Price Expiration Date 360,000 $ 2.00 June 28, 2026 29,067 3.00 December 22, 2027 4,933 3.00 January 10, 2028 6,720 3.00 March 31, 2028 400,720

The Company (Details)

The Company (Details)	9 Months Ended
	Mar. 31, 2023 shares
The Company [Abstract]
Common stock shares	1.299135853
Capital stock equal shares	4,100,000
Aggregate shares	2,500,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Accounting Policies [Abstract]
Net loss	$ 4,071,391		$ 3,451,699
Research & development expenses	$ 350,195	$ 165,956
Amortized over the remaining lease term	5 years
Amortized on a straight-line basis	5 years
Interest and penalties	$ 0

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)								9 Months Ended
	May 10, 2023	Jan. 10, 2023	Dec. 12, 2022	Jul. 01, 2021	Jun. 28, 2021	Jun. 22, 2021	Oct. 27, 2020	Mar. 31, 2023	Jun. 30, 2022
Stockholders’ Equity (Details) [Line Items]
Common stock, shares authorized								50,000,000	50,000,000
Common stock, per share								$ 0.0001	$ 0.0001
Preferred stock, shares authorized								10,000,000	10,000,000
Preferred stock, par value								$ 0.0001	$ 0.0001
Preferred shares issued
Gross proceeds		$ 644,000	$ 1,551,000					$ 4,342,000
Placement agent fees and expenses		$ 28,640				$ 949,736
Shares of common stock								1,447,332
Offering cost			$ 124,385
Aggregate shares	570,166	214,667						715,665
Aggregate gross proceeds								$ 2,147,000
Before deducting placement agent fees and expenses								$ 117,830
Issued and vested shares, description							the Company issued 1,623,920 shares of common stock to Director and CEO Jonathan Klamkin and 1,623,920 shares of common stock to Director, interim CFO and COO, Lee McCarthy for an aggregate sum of $10,000 each. Initially 20% or 324,784 shares vested on October 27, 2020, and the remaining 1,299,136 shares vest in equal amounts, monthly over the subsequent 4 years. The stock purchase agreement contains a repurchase option whereby unvested shares may be repurchased by the Company, at the Company’s option, within 90 days after employee termination.
Vested shares								1,109,679
Unvested shares								514,241
Agreement percentage								8%
Covered shares								11,010,002
Offering [Member]
Stockholders’ Equity (Details) [Line Items]
Placement agent fees and expenses								$ 1,082,577
Private Placement [Member]
Stockholders’ Equity (Details) [Line Items]
Offering price per share			$ 3
Common Stock [Member]
Stockholders’ Equity (Details) [Line Items]
Gross proceeds				$ 230,000	$ 805,000	$ 6,965,000		8,000,000
Placement agent fees and expenses				$ 23,070	$ 109,769			$ 270,855
Shares of common stock				115,000	402,500			4,000,000
Private Placement [Member]
Stockholders’ Equity (Details) [Line Items]
Shares of common stock			517,000
Private Placement [Member]
Stockholders’ Equity (Details) [Line Items]
Common stock offering price						3,482,500
Purchase price, per share						$ 2
Lee McCarthy [Member]
Stockholders’ Equity (Details) [Line Items]
Vested shares								974,350
Unvested shares								649,570

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

Dec. 31, 2022

Feb. 04, 2022

Feb. 01, 2022

Apr. 30, 2022

Mar. 31, 2022

Dec. 31, 2021

Jul. 31, 2021

Mar. 31, 2023

Mar. 31, 2022

Jun. 30, 2021

Mar. 31, 2023

Mar. 31, 2022

Stock-Based Compensation (Details) [Line Items]

Sale of common stock (in Shares)

723,008

Amortized value

$ 163,347

$ 163,348

$ 497,302

$ 497,303

Deferred compensation

176,196

176,196

Issue of share (in Shares)

150,000

Common stock value

$ 300,000

300,000

300,000

Expensed

$ 50,000

$ 208,000

Stock issued during period (in Shares)

150,000

Expiring year

10 years

Stock based compensation expense description

In December 2021, the Company issued options to purchase common stock to two directors in increments of 125,000 each. The options have an exercise price of $2.00, expire in 10 years, vest 12,500 options per quarter in the first year and 9,375 per quarter for the following two years. In February of 2022, the company granted 16,750 in options to one director and 15,500 to another director at a price of $2.00 per share, for committee service. These options are subject to quarterly vesting over four quarters and expire in 10 years.

Option grant

$ 127,102

$ 41,114

$ 304,553

$ 70,783

Unrecognized stock-based compensation expense

$ 1,292,801

Average expected recognition period

2 years 9 months 18 days

Fair value excess per share (in Dollars per share)

$ 2

Excess of fair value price per share (in Dollars per share)

$ 3.6

Common Stock [Member]

Stock-Based Compensation (Details) [Line Items]

Deferred compensation

$ 92,000

$ 92,000

Issue of share (in Shares)

150,000

Minimum [Member]

Stock-Based Compensation (Details) [Line Items]

Excess of fair value price per share (in Dollars per share)

$ 0.0104

Vesting terms

2 years

Fair value excess per share (in Dollars per share)

$ 3

Maximum [Member]

Stock-Based Compensation (Details) [Line Items]

Excess of fair value price per share (in Dollars per share)

$ 0.0195

Vesting terms

4 years

Fair value excess per share (in Dollars per share)

$ 3.6

Director [Member]

Stock-Based Compensation (Details) [Line Items]

Excess of fair value price per share (in Dollars per share)

$ 2

Issued shares (in Shares)

10,000

Expiring year

10 years

Advisor [Member]

Stock-Based Compensation (Details) [Line Items]

Excess of fair value price per share (in Dollars per share)

$ 2

Issued shares (in Shares)

10,000

Expiring year

10 years

5 years

Grants option shares (in Shares)

2,500

Exercise price per share (in Dollars per share)

$ 2

Employees [Member]

Stock-Based Compensation (Details) [Line Items]

Issued shares (in Shares)

513,000

Expiring year

10 years

Exercise price per share (in Dollars per share)

$ 2

Vesting percentage

25%

Employees and Directors [Member]

Stock-Based Compensation (Details) [Line Items]

Issued shares (in Shares)

109,750

109,750

Expiring year

10 years

Exercise price per share (in Dollars per share)

$ 3

Non-Employee Advisors [Member]

Stock-Based Compensation (Details) [Line Items]

Issued shares (in Shares)

37,500

37,500

Exercise price per share (in Dollars per share)

$ 3

Advisory Agreement [Member]

Stock-Based Compensation (Details) [Line Items]

Grants option shares (in Shares)

2,500

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of restricted stock awards - $ / shares	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Schedule of Restricted Stock Awards [Abstract]
Number of Shares, beginning balance	296,022	517,828	344,426	691,232
Weighted Average Grant Date Fair Value per Price, Outstanding beginning balance	$ 1.95	$ 1.9	$ 1.9	$ 1.9
Number of Shares, ending balance	171,820	431,126	171,820	431,126
Weighted Average Grant Date Fair Value per Price, Outstanding ending balance	$ 1.95	$ 1.9	$ 1.95	$ 1.9
Number of Shares, Issued			150,000
Weighted Average Grant Date Fair Value per Price, Issued			$ 2
Number of Shares, Vested	(124,202)	(86,702)	(322,606)	(260,106)
Weighted Average Grant Date Fair Value per Price, Vested	$ 1.93	$ 1.9	$ 1.92	$ 1.9
Number of Shares, Forfeited
Weighted Average Grant Date Fair Value per Price, Forfeited

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of estimates the fair value of each option award - $ / shares	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock-Based Compensation (Details) - Schedule of estimates the fair value of each option award [Line Items]
Weighted-average fair value (in Dollars per share)	$ 2.49	$ 1.48
Expected volatility	100%	100%
Expected term		5 years
Dividend yield	0%	0%
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of estimates the fair value of each option award [Line Items]
Expected term	5 years
Risk-free interest rate	1.26%	1.15%
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of estimates the fair value of each option award [Line Items]
Expected term	7 years
Risk-free interest rate	4.24%	2.41%

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of summarizing employee and non-employee stock option activity - USD ($)	3 Months Ended			9 Months Ended
	Mar. 31, 2023		Mar. 31, 2022	Mar. 31, 2023		Mar. 31, 2022
Schedule of Summarizing Employee and Non Employee Stock Option Activity [Abstract]
Number of Options, Beginning Balance (in Shares)	858,750		270,000	817,750
Weighted Average Exercise Price, Beginning Balance	$ 2.01		$ 2	$ 2
Aggregate Intrinsic Value, Beginning Balance (in Dollars)	$ 846,250	[1]			[2]
Number of Options, Granted (in Shares)	147,250		34,750	308,250		304,750
Weighted Average Exercise Price, Granted	$ 3		$ 2	$ 2.41		$ 2
Number of Options, Exercised (in Shares)
Weighted Average Exercise Price, Exercised
Number of Options, Expired/cancelled (in Shares)				(120,000)
Weighted Average Exercise Price, Expired/cancelled				$ 2
Number of Options, Ending balance (in Shares)	1,006,000		304,750	1,006,000		304,750
Weighted Average Exercise Price, Ending balance	$ 2.16		$ 2	$ 2.16		$ 2
Aggregate Intrinsic Value, Ending balance (in Dollars)	$ 1,449,850	[1],[2]		$ 1,449,850	[1],[2]
Number of Options, Exercisable (in Shares)	307,375		47,500	307,375		47,500
Weighted Average Exercise Price, Exercisable	$ 2.02		$ 2	$ 2.02		$ 2
Aggregate Intrinsic Value, Exercisable (in Dollars)	$ 486,613	[1],[2]		$ 486,613	[1],[2]
[1]Represents the excess of the fair value on the last day of period (which was $3.00 and $3.60 as of December 31, 2022 and March 31, 2023, respectively) over the exercise price, multiplied by the number of options.[2]Represents the excess of the fair value on the last day of the period (which was $3.60 as of March 31, 2023) over the exercise price, multiplied by the number of options.

Facility Operating Lease (Detai

Facility Operating Lease (Details) - USD ($)		3 Months Ended		9 Months Ended
	Apr. 01, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Facility Operating Lease
Operating lease commencement, description	On April 1, 2021, the Company commenced a 5-year operating lease for a facility in Santa Barbara, California with total lease payments of $781,813.
Operating lease payments	$ 767,553
Operating lease term		3 years		3 years
Operating lease discount rate		0.75%		0.75%
Total lease payment		$ 24,360	$ 39,041	$ 97,078	$ 117,124
Variable costs		54,643	55,516	228,454	173,488
Lease description	The sub-lease provides for base monthly rent of $13,013 through May 31, 2021 and $8,400 starting June 1, 2021 plus common area operating and utility costs. The sublease was amended again on May 17, 2022 to sublease a smaller portion of the property at a base rental rate of $5,200 per month effective June 1, 2022.
Rent income		$ 23,405	$ 55,689	$ 128,921	$ 227,589

Facility Operating Lease (Det_2

Facility Operating Lease (Details) - Schedule of maturities of operating lease liabilities	Mar. 31, 2023 USD ($)
Schedule of Maturities of Operating Lease Liabilities [Abstract]
Fiscal 2023	$ 41,017
Fiscal 2024	165,096
Fiscal 2025	169,224
Fiscal 2026	129,283
Total	504,620
Less imputed interest	(5,850)
Total operating lease liability	498,770
Less: current portion	160,882
Lease liability, long term	$ 337,888

Warrants to Purchase Common S_3

Warrants to Purchase Common Stock (Details) - $ / shares		9 Months Ended
	Jan. 10, 2023	Mar. 31, 2023	Dec. 22, 2022	Jun. 30, 2022
Warrants to Purchase Common Stock (Details) [Line Items]
Purchase of common stock		12,247,334	29,067	10,650,002
Warrants term		5 years
Exercise price (in Dollars per share)		$ 3
Warrants of shares issued	4,933	6,720
Warrant [Member]
Warrants to Purchase Common Stock (Details) [Line Items]
Warrants term		5 years
Exercise price (in Dollars per share)		$ 3

Warrants to Purchase Common S_4

Warrants to Purchase Common Stock (Details) - Schedule of warrants to purchase common stock	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Shares	400,720
Exercise Price 2.00 [Member]
Class of Warrant or Right [Line Items]
Number of Shares	360,000
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jun. 28, 2026
Exercise Price 3.00 [Member]
Class of Warrant or Right [Line Items]
Number of Shares	29,067
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Dec. 22, 2027
Exercise Price 3.00 [Member]
Class of Warrant or Right [Line Items]
Number of Shares	4,933
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Jan. 10, 2028
Exercise Price 3.00 [Member]
Class of Warrant or Right [Line Items]
Number of Shares	6,720
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Mar. 31, 2028

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)			9 Months Ended
	May 10, 2023	Jan. 10, 2023	Mar. 31, 2023
Subsequent Events [Abstract]
Aggregate shares	570,166	214,667	715,665
Gross proceeds	$ 1,710,500
Agent fee	$ 136,840
Warrants purchase	44,933
Exercise price	$ 3